# Annovis Bio, Inc.: financial statements, quarterly

ANVS · NYSE · CIK 1477845 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/anvs.md) · [Financials](/companies/anvs/financials.md) · [Filings](/companies/anvs/filings.md) · [Insiders](/companies/anvs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/anvs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0 d](/filings/0001558370-23-018298.md) | [0.0 d](/filings/0001558370-24-004393.md) | [0.0](/filings/0001558370-24-007820.md) | [0.0 d](/filings/0001558370-24-012227.md) | [0.0 d](/filings/0001558370-24-015074.md) | [0.0 d](/filings/0001558370-25-003482.md) | [0.0](/filings/0001558370-25-007584.md) | [0.0 d](/filings/0001558370-25-011233.md) | [0.0 d](/filings/0001104659-25-110393.md) | [0.0 d](/filings/0001104659-26-027751.md) | [0.0](/filings/0001104659-26-062626.md) | [0.0 d](/filings/0001104659-26-097228.md) |
| Research and development | $m | [13.8](/filings/0001558370-24-015074.md) | [8.9 d](/filings/0001558370-25-003482.md) | [6.5](/filings/0001558370-25-007584.md) | [5.8](/filings/0001558370-25-011233.md) | [2.7](/filings/0001104659-25-110393.md) | [5.0 d](/filings/0001104659-26-027751.md) | [5.0](/filings/0001104659-26-062626.md) | [5.2](/filings/0001104659-26-097228.md) | [6.3](/filings/0001104659-25-110393.md) | [8.8 d](/filings/0001104659-26-027751.md) | [16.7](/filings/0001104659-26-062626.md) | [12.0](/filings/0001104659-26-097228.md) |
| Operating income | $m | [(14.9)](/filings/0001558370-24-015074.md) | [(10.4) d](/filings/0001558370-25-003482.md) | [(7.8)](/filings/0001558370-25-007584.md) | [(7.8)](/filings/0001558370-25-011233.md) | [(4.4)](/filings/0001104659-25-110393.md) | [(6.7) d](/filings/0001104659-26-027751.md) | [(6.3)](/filings/0001104659-26-062626.md) | [(6.3)](/filings/0001104659-26-097228.md) | [(7.4)](/filings/0001104659-25-110393.md) | [(9.7) d](/filings/0001104659-26-027751.md) | [(18.0)](/filings/0001104659-26-062626.md) | [(14.4)](/filings/0001104659-26-097228.md) |
| Income tax | $m | [0.0](/filings/0001558370-24-015074.md) | not reported | [0.0](/filings/0001558370-25-007584.md) | [0.0](/filings/0001558370-25-011233.md) | [0.0](/filings/0001104659-25-110393.md) | not reported | [0.0](/filings/0001104659-26-062626.md) | [0.0](/filings/0001558370-25-011233.md) | [0.0](/filings/0001104659-25-110393.md) | [0.0 d](/filings/0001104659-26-027751.md) | [0.0](/filings/0001104659-26-062626.md) | [0.0](/filings/0001104659-26-097228.md) |
| Net income | $m | [(14.7)](/filings/0001558370-24-015074.md) | [(22.2) d](/filings/0001558370-25-003482.md) | [(1.1)](/filings/0001104659-25-110393.md) | [(5.0)](/filings/0001104659-25-110393.md) | [(12.6)](/filings/0001104659-25-110393.md) | [(5.9) d](/filings/0001104659-26-027751.md) | [(5.5)](/filings/0001104659-26-097228.md) | [(6.2)](/filings/0001104659-26-097228.md) | [(7.3)](/filings/0001104659-25-110393.md) | [(9.8) d](/filings/0001104659-26-027751.md) | [(17.6)](/filings/0001104659-26-097228.md) | [(14.8)](/filings/0001104659-26-097228.md) |
| Diluted EPS | $ per share | [(1.63)](/filings/0001558370-24-015074.md) | not reported | [(0.72)](/filings/0001558370-25-007584.md) | [(0.44)](/filings/0001558370-25-011233.md) | [(0.97)](/filings/0001104659-25-110393.md) | not reported | [(0.32)](/filings/0001104659-26-062626.md) | [(0.32)](/filings/0001104659-26-097228.md) | [(0.37)](/filings/0001104659-25-110393.md) | not reported | [(0.63)](/filings/0001104659-26-062626.md) | [(0.40)](/filings/0001104659-26-097228.md) |
| Basic EPS | $ per share | [(1.63)](/filings/0001558370-24-015074.md) | not reported | [(0.10)](/filings/0001558370-25-007584.md) | [(0.44)](/filings/0001558370-25-011233.md) | [(0.97)](/filings/0001104659-25-110393.md) | not reported | [(0.32)](/filings/0001104659-26-062626.md) | [(0.32)](/filings/0001104659-26-097228.md) | [(0.37)](/filings/0001104659-25-110393.md) | not reported | [(0.63)](/filings/0001104659-26-062626.md) | [(0.40)](/filings/0001104659-26-097228.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [6.4](/filings/0001558370-23-018298.md) | [5.8](/filings/0001558370-25-003482.md) | [3.1](/filings/0001558370-24-007820.md) | [4.0](/filings/0001558370-24-012227.md) | [12.6](/filings/0001558370-24-015074.md) | [10.6](/filings/0001104659-26-027751.md) | [22.2](/filings/0001558370-25-007584.md) | [17.1](/filings/0001558370-25-011233.md) | [15.3](/filings/0001104659-25-110393.md) | [19.5](/filings/0001104659-26-097228.md) | [14.2](/filings/0001104659-26-062626.md) | [18.7](/filings/0001104659-26-097228.md) |
| Current assets | $m | [10.2](/filings/0001558370-23-018298.md) | [10.2](/filings/0001558370-24-007820.md) | [7.8](/filings/0001558370-24-007820.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total assets | $m | [10.2](/filings/0001558370-23-018298.md) | [10.2](/filings/0001558370-25-003482.md) | [7.8](/filings/0001558370-24-007820.md) | [5.0](/filings/0001558370-24-012227.md) | [14.4](/filings/0001558370-24-015074.md) | [13.9](/filings/0001104659-26-027751.md) | [26.7](/filings/0001558370-25-007584.md) | [21.5](/filings/0001558370-25-011233.md) | [17.2](/filings/0001104659-25-110393.md) | [21.1](/filings/0001104659-26-097228.md) | [16.2](/filings/0001104659-26-062626.md) | [22.0](/filings/0001104659-26-097228.md) |
| Current liabilities | $m | [3.6](/filings/0001558370-23-018298.md) | [4.3](/filings/0001558370-25-003482.md) | [4.9](/filings/0001558370-24-007820.md) | [4.1](/filings/0001558370-24-012227.md) | [5.4](/filings/0001558370-24-015074.md) | [3.9](/filings/0001104659-26-027751.md) | [2.5](/filings/0001558370-25-007584.md) | [2.8](/filings/0001558370-25-011233.md) | [3.7](/filings/0001104659-25-110393.md) | [3.6](/filings/0001104659-26-097228.md) | [12.8](/filings/0001104659-26-062626.md) | [6.4](/filings/0001104659-26-097228.md) |
| Total liabilities | $m | [3.6](/filings/0001558370-23-018298.md) | [18.0](/filings/0001558370-25-003482.md) | [11.2](/filings/0001558370-24-007820.md) | [6.8](/filings/0001558370-24-012227.md) | [7.3](/filings/0001558370-24-015074.md) | [4.6](/filings/0001104659-26-027751.md) | [2.7](/filings/0001558370-25-007584.md) | [3.1](/filings/0001558370-25-011233.md) | [4.0](/filings/0001104659-25-110393.md) | [4.2](/filings/0001104659-26-097228.md) | [13.1](/filings/0001104659-26-062626.md) | [26.3](/filings/0001104659-26-097228.md) |
| Shareholders' equity | $m | [6.7](/filings/0001558370-24-015074.md) | [(7.8)](/filings/0001104659-26-027751.md) | [(3.4)](/filings/0001104659-25-110393.md) | [(1.8)](/filings/0001104659-25-110393.md) | [7.1](/filings/0001104659-25-110393.md) | [9.3](/filings/0001104659-26-097228.md) | [24.1](/filings/0001104659-26-097228.md) | [18.3](/filings/0001104659-26-097228.md) | [13.2](/filings/0001104659-25-110393.md) | [16.9](/filings/0001104659-26-097228.md) | [3.1](/filings/0001104659-26-097228.md) | [(4.3)](/filings/0001104659-26-097228.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(9.4) d](/filings/0001558370-24-015074.md) | [(9.4) d](/filings/0001558370-25-003482.md) | [(7.0)](/filings/0001558370-25-007584.md) | [(3.4) d](/filings/0001558370-25-011233.md) | [(3.2) d](/filings/0001104659-25-110393.md) | [(8.3) d](/filings/0001104659-26-027751.md) | [(8.1)](/filings/0001104659-26-062626.md) | [(5.1) d](/filings/0001104659-26-097228.md) | [(3.5) d](/filings/0001104659-25-110393.md) | [(8.9) d](/filings/0001104659-26-027751.md) | [(9.0)](/filings/0001104659-26-062626.md) | [(21.9) d](/filings/0001104659-26-097228.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [8.2](/filings/0001558370-23-018298.md) | [9.0](/filings/0001558370-24-012227.md) | [9.0](/filings/0001558370-24-012227.md) | [9.0](/filings/0001558370-24-015074.md) | [10.8](/filings/0001558370-25-007584.md) | [11.3](/filings/0001558370-25-011233.md) | [13.0](/filings/0001104659-25-110393.md) | [17.4](/filings/0001104659-26-062626.md) | [19.5](/filings/0001104659-26-097228.md) | [19.7](/filings/0001104659-25-110393.md) | [27.8](/filings/0001104659-26-062626.md) | [37.5](/filings/0001104659-26-097228.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 42,606,152 at 2026-08-14, from the cover of the [10-Q filed 2026-08-14](/filings/0001104659-26-097228.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.